The choice of the right treatment regimen for recurrent ovarian cancer (rOC) remains a case-by-case decision. It is based on multiple factors that involve patient characteristics and biological factors at the same time. The prioritization of factors is still subject to changes with a trend towards a more personalized medicine. Therefore, participation and engagement in clinical studies constitutes a substantial need for the future development of the treatment algorithm of rOC.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1007/s11864-020-00747-7 | DOI Listing |
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!